1Q preview: AbbVie, Amgen, AstraZeneca, Biogen, Lilly, Novartis, Roche
This article was originally published in Scrip
Executive Summary
Johnson & Johnson set the tone for the first-quarter pharma financial reporting season on 14 April when it reported a 4% drop in sales due to currency fluctuations, although pharma beat expectations.